Proposed definitions of antibody-mediated rejection for use as a clinical trial endpoint in kidney transplantation

समान संसाधन

• Proposed definitions of T cell-mediated rejection and tubulointerstitial inflammation as clinical trial endpoints in kidney transplantation
  द्वारा: Seron, D, और अन्य
  प्रकाशित: (2022)
• Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation
  द्वारा: Naesens, M, और अन्य
  प्रकाशित: (2022)
• Allograft function as endpoint for clinical trials in kidney transplantation
  द्वारा: Hilbrands, L, और अन्य
  प्रकाशित: (2022)
• Alloimmune risk stratification for kidney transplant rejection
  द्वारा: Bestard, O, और अन्य
  प्रकाशित: (2022)
• Patient-reported outcomes as endpoints in clinical trials of kidney transplantation interventions
  द्वारा: Tong, A, और अन्य
  प्रकाशित: (2022)